Finance

Lists
SABS:NASDAQ
SAB Biotherapeutics Inc
၃.၇၉ US$
-၃.၅၆%
(-၀.၁၄) 1D
ဩ ၂၈, GMT-၄ ၁၆:၀၀:၀၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
၃.၉၁ US$
High
၃.၉၉ US$
Low
၃.၇၈ US$
Mkt. cap
၃၄.၄၈ ကုဋေ
Avg. vol.
၄.၄၂ သိန်း
Volume
၀.၀၀
52-wk high
၅.၁၅ US$
52-wk low
၁.၈၅ US$
EPS
-၀.၆၃ US$
Beta
၀.၅၂
Shares outstanding
၉.၁၀ ကုဋေ
No. of employees
၈၆
Open
၃.၉၁ US$
High
၃.၉၉ US$
Low
၃.၇၈ US$
Mkt. cap
၃၄.၄၈ ကုဋေ
Avg. vol.
၄.၄၂ သိန်း
Volume
၀.၀၀
52-wk high
၅.၁၅ US$
52-wk low
၁.၈၅ US$
EPS
-၀.၆၃ US$
Beta
၀.၅၂
Shares outstanding
၉.၁၀ ကုဋေ
No. of employees
၈၆
About SAB Biotherapeutics Inc
CEO-
Employees၈၆
Founded၂၀၁၄
HeadquartersMiami Beach, ဖလော်ရီဒါပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitesab.bio
Analyst ratings
Based on 7 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current ၃.၇၉ US$
၁၆.၀၀ US$ (+၃၂၂.၁၆%)
Average
၁၂.၁၄ US$ (+၂၂၀.၃၂%)
Lowest
၆.၀၀ US$ (+၅၈.၃၁%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Buy
Maintained
၁၃.၀၀ US$
+၂၄၃%
08/07/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
၁၀.၀၀ US$
+၁၆၃.၉%
08/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
၁၅.၀၀ US$
+၂၉၅.၈%
08/07/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
၁၆.၀၀ US$
+၃၂၂.၂%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
၆.၀၀ US$
+၅၈.၃%
06/16/2026
Samantha Semenkow
Citi
Buy
Reiterated
၁၁.၀၀ US$
+၁၉၀.၂%
06/15/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
၁၄.၀၀ US$
+၂၆၉.၄%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
၁၁.၀၀ US$
+၁၉၀.၂%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
၁၅.၀၀ US$
+၂၉၅.၈%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
၁၃.၀၀ US$
+၂၄၃%
04/02/2026
Michael Yee
UBS
Buy
Maintained
၇.၀၀ US$
+၈၄.၇%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
၈.၉၇ သန်း
၉.၇၃ သန်း
၁.၃၄ ကုဋေ
၁.၆၂ ကုဋေ
Cost of revenue
၈.၉၇ သန်း
၉.၇၃ သန်း
၁.၃၄ ကုဋေ
၁.၆၂ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၃.၇၁ သန်း
၆.၀၄ သန်း
၆.၆၀ သန်း
၇.၂၀ သန်း
Operating expense
၃.၇၁ သန်း
၆.၀၄ သန်း
၆.၆၀ သန်း
၇.၂၀ သန်း
Total operating expenses
၁.၂၇ ကုဋေ
၁.၅၈ ကုဋေ
၂.၀၀ ကုဋေ
၂.၃၄ ကုဋေ
Operating income
-၁.၂၇ ကုဋေ
-၁.၅၈ ကုဋေ
-၂.၀၀ ကုဋေ
-၂.၃၄ ကုဋေ
Other non operating income
၅.၇၅ ကုဋေ
-၁.၇၃ သန်း
၁.၄၄ သိန်း
-၇.၆၁ သိန်း
EBT including unusual items
၄.၅၄ ကုဋေ
-၁.၆၉ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၂၅ ကုဋေ
EBT excluding unusual items
၄.၅၄ ကုဋေ
-၁.၆၉ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၂၅ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
၄.၅၄ ကုဋေ
-၁.၆၉ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၂၅ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-
-၀.၄၁
-
-၀.၂၈
Interest and investment income
၆.၅၅ သိန်း
၇.၀၁ သိန်း
၁.၀၅ သန်း
၁.၇၁ သန်း
Interest expense
-၄.၃၃ သောင်း
-၆.၃၅ သောင်း
-၆.၂၇ သောင်း
-၆.၂၀ သောင်း
Net interest expenses
၆.၁၂ သိန်း
၆.၃၇ သိန်း
၉.၈၄ သိန်း
၁.၆၅ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၁၉ ကုဋေ
-၁.၅၀ ကုဋေ
-၁.၉၂ ကုဋေ
-၂.၂၅ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google အက်ပ်များ